



MINISTÈRE
DE L'ENSEIGNEMENT
SUPÉRIEUR
ET DE LA RECHERCHE

*Liberté
Égalité
Fraternité*



RÉUNION D'INFORMATION IHI PAR IHI

INNOVATIVE HEALTH INITIATIVE JU

13 OCTOBRE 2025



MINISTÈRE
DE L'ENSEIGNEMENT
SUPÉRIEUR
ET DE LA RECHERCHE

*Liberté
Égalité
Fraternité*



Ordre du jour

10 :00 Café networking

10 :30 Présentation Call 12 IHI.

Magali Poinot **Governance leader IHI**

11 :00 Call 12 du point de vue de l'industrie

Nicolas Cleff **EFPIA**, Phillipe Bordier **Sanofi**, Natalie de Préville **Servier**

Enrique Esquivel **COCIR**

Sophie Koettlitz **Medtech**

11 :30 Questions, échanges

12 :00 fin de réunion



Vania Rosas-Magallanes, MESR

Coordinatrice du PCN Santé

Experte au Comité de programme Santé – Horizon Europe



Roxane Brachet (40%)

Membre du PCN Santé




Kévin Plouchart (40%)

Membre du PCN Santé



Catherine Tostain Desmares (40%)

Membre du PCN Santé



Contactez-nous: pcn-sante@recherche.gouv.fr

Nous suivre sur **LinkedIn** 

Inscrivez-vous sur notre [liste de diffusion](#)



Introducing IHI Call 12

Boosting innovation for a
competitive European health
ecosystem

13.10.2025

Magali Poinot


Team Leader
Governance




IHI in a nutshell

We are a public-private partnership...

The partners contribute equally to our €2.4 billion budget




IHI's purpose – from objectives to impacts



What does an IHI project look like?

IHI projects are...





Introducing Call 12

Boosting innovation for a competitive
European health ecosystem through
an applicant-driven approach



IHI Call 12

- New applicant-driven Call, taking into account experience from pilot Call 9.
- Create additional research opportunities and harness new science and technologies through a broad scope.
- Be attractive to innovative proposals and to a range of new stakeholders including smaller players, private members that might be not already involved in IHI activities.
- Provide opportunities for new cross sectoral collaborations in line with IHI's general and specific objectives.
- Enhance openness and co-creation of research ideas to projects.

Unless stated otherwise, all information regarding future IHI call topics is indicative and subject to change. Final information about future IHI calls is communicated after approval by the IHI Governing Board.

IHI Call 12

Boosting innovation for a competitive European health ecosystem



Strategic Research
and Innovation
Agenda



- IHI Call 12 comprises 5 topics, each focusing on one of the five IHI Specific Objectives (SOs)
- The call contains an introduction and general elements to be considered for all topics
- The overall aim is to fund pre-competitive research and innovation actions that are in line with the general objectives of IHI and address at least one of IHI SOs as set out in the IHI [Strategic Research and Innovation Agenda \(SRIA\)](#)

It is important to read carefully the introduction to the Call and general elements to be considered for all topics

NB - In the context of IHI, pre-competitive refers to collaborative research among potential competitors addressing common challenges, building knowledge and developing foundational technologies or standards that benefit all the actors in that research space, rather individual companies.



IHI Call 12 – 5 topics

Topic 1: Boosting innovation for a better understanding of the determinants of health

Addressing SO1: *“contribute towards a better understanding of the determinants of health and priority disease areas”*

Topic 2: Boosting innovation through better integration of fragmented health R&I efforts

Addressing SO2: *“integrate fragmented health research & innovation efforts bringing together health industry sectors and other stakeholders, focusing on unmet public health needs, to enable the development of tools, data, platforms, technologies & processes for improved prediction, prevention, interception, diagnosis, treatment and management of diseases, meeting the needs of end-users”*

Topic 3: Boosting innovation for people-centred integrated healthcare solutions

Addressing SO3: *“demonstrate the feasibility of people-centred integrated healthcare solutions”*



IHI Call 12 – Topics cont.

Topic 4: Boosting innovation through exploitation of digitalisation and data exchange in healthcare

Addressing SO4: *“exploit the full potential of digitalisation and data exchange in healthcare”*

Topic 5: Boosting innovation for better assessment of the added value of innovative integrated healthcare solutions

Addressing SO5: *“enable the development of new and improved evaluation methodologies and models for a comprehensive assessment of the added value of innovative and integrated healthcare solutions.”*



General elements to be considered for all topics

- Most activities are expected to be cross-sectoral, and may cover the whole health innovation chain including but not limited to:
 - discovery of new molecules, mechanisms of action, processes, technologies;
 - development and testing of these discoveries;
 - development of methodologies for assessment of safety, health outcomes or health-economic evaluation;
 - standardisation activities;
 - contribution to regulatory science;
 - pilots/proofs of feasibility including in-silico trials.



General elements to be considered for all topics

- Proposals that aim to demonstrate the feasibility and/or scalability of integrating solutions into national or regional healthcare systems and/or of innovations are welcomed.
 - ✓ Remember: Research should remain at the pre-competitive level and translate into solutions that can be applied by all players in the ecosystem.
- Proposals can only be submitted under one topic, so please consider which Specific Objective is the most relevant to the primary focus of your proposal and submit it only under the corresponding topic.
- Applicants must clearly justify the alignment of the objectives of their proposed work with the Specific Objective selected. Considering the complementarity of the IHI JU Specific Objectives, proposals may also cover aspects related to other Specific Objective(s). If so, applicants should also highlight this in their proposal



IHI Call 12 - Scope for each topic

Assemble a **collaborative public-private partnership consortium** reflecting the integrative and cross-sectoral nature of IHI that is capable of addressing the challenge(s) and scope of the selected IHI Specific Objective and described in more detail in the IHI SRIA.

Applicants should consider the following points in their proposals:

- a) Address an unmet public health need** based on at least one of the below:
- high burden of disease for patients and/or society
 - high economic impact of the disease for patients and society;
 - transformational nature of the potential results on innovation processes



IHI Call 12 - Scope for each topic

- b) Demonstrate the ability to translate research into innovative solutions** that can be integrated/implemented into the healthcare ecosystem and/or in industrial processes.
- c) Carry out a landscape analysis** to avoid unnecessary overlap and duplication of efforts with existing initiatives/projects and to identify potential synergies and complementarities with the relevant ones. The proposal should include a plan on how to synergise with these identified initiatives.

When applicable, relevant aspects of **patient-centricity** to be considered



IHI Call 12 - Expected outcomes for each topic

- Outcomes to be defined by the applicants, ensuring that they contribute to at least one of IHI's potential outputs linked to the relevant Specific Objective as set out in the [IHI SRIA](#)
- Address public health needs and support the development of future health innovations that are safe, people-centred, effective, cost-effective and affordable for patients and for health care systems. Expect also to benefit the relevant stakeholders in the healthcare ecosystem.
- May cover the entire spectrum of care and be centred around disease areas, key themes or approaches such as prevention, personalised medicine, and chronic disease management. They may also include enabling solutions for digitalisation, artificial intelligence, regulatory science, greener and more sustainable healthcare, and the deployment and use of these solutions into practice.



IHI Call 12 - Expected impacts

The actions to be funded are expected to contribute to:

- one or more IHI JU's expected impacts linked to the Specific Objective selected as set out in the IHI JU SRIA.
- strengthening the competitiveness of the EU's health industry
- the implementation of relevant aspects of the [EU's Life Sciences Strategy](#) (topic specific e.g. unlocking the power of new knowledge, data and AI for breakthrough innovation for topic 4)



IHI Call 12 timeline



Mid-October publication of the draft call text on our [website](#)

4-5 Nov: Face-to-face [brokerage event](#) in Brussels

Watch out in **early 2026** for:

- The official launch of the call
- Online info sessions with details of the call, IHI rules and procedures and the financial aspects of the proposal

The [brokerage platform](#) will remain **open** for registration and networking until the call deadline.



Preparing your Call 12 application

What you should also think about!



Call 12 is a single-stage IHI call

You need to build / join a public-private partnership

Read our:
[*Guide for Applicants*](#)
and other
[*key call documents*](#)



Funding

Half (**minimum 45%**) of the project's costs must come via contributions from IHI industry members and (if relevant) contributing partners.

Consortium size

At least 1 organisation established in an EU Member State + 2 organisations established in the EU or a country associated to Horizon Europe.



Entities eligible for funding



Restrictions regarding eligibility for funding for entities based in countries recently associated to Horizon Europe.
Read carefully the call topics



Evaluation criteria - Excellence

- **Clarity and pertinence of the project's objectives**, and the extent to which the proposed work is **ambitious**, and goes **beyond the state-of-the-art**.
- **Soundness of the proposed methodology**, including the underlying concepts, models, assumptions, inter-disciplinary approaches; appropriate consideration of the **gender dimension** in research and innovation content; and the quality of **open science practices** including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.



Evaluation criteria - Impact

- **Credibility of the pathways to achieve the expected outcomes and impacts** specified in the work programme, and the likely scale and significance of the contributions due to the project.
- **Suitability and quality of the measures to maximize expected outcomes and impacts**, as set out in the dissemination and exploitation plan, including communication activities.



Evaluation criteria – Quality and efficiency of the Implementation

- **Quality and effectiveness of the work plan**, assessment of risks (including risk of falling below 45% contribution threshold), appropriateness of the effort assigned to work packages, and the resources overall.
- **Capacity and role of each participant**, and extent to which the consortium as a whole establishes a public-private collaboration and brings together the necessary expertise. If relevant capacity and role of the contributing partner(s) to the consortium.
- **Clearly defined and effective integration of in-kind and financial contributions of IHI JU private members**, their constituent or affiliated entities to enable a successful public-private partnership. If relevant clearly defined and effective integration of in-kind and financial contribution of contributing partner(s).



5 steps to success!

1. **Study** the IHI Strategic Research & Innovation Agenda
2. **Showcase your expertise** on our online network platform
3. **Get networking** online and at our Call 12 brokerage event on 4-5 November 2025
4. **Share your project proposal** on our platform and via a pitch at the Call 12 brokerage event
5. **Make sure you understand IHI**





Call 9, pilot of an open, applicant-led approach

Quick overview


Call 9 - summary of call outcome

	Proposals submitted	Eligible/ Admissible	Above threshold	Retained for funding
Topic 1	8	6	3	2
Topic 2	18	16	12	5
Topic 3	11	7	5	3
Topic 4	8	7	3	2
Topic 5	5	3	2	1
TOTAL	50	39	25	13 (26%)
Requested EU contribution (M)		€528.4	€383.2	€204.8
Total IK* (EU and non-EU) (M)		€415.8	€297.8	€156.6

*Does not include IKAA

Geographical distribution (EU) of applicants in proposals retained for funding

IHI Call 9 Applicants in Mainlisted Proposals (Europe)





Call 9, where did it lead us?

“

13 funded proposals

€ 363m total budget

46 new entities

Artificial Intelligence in health – *major component in 10 out 13 / all required an “AI Assessment” during evaluation*

Cardiovascular health

Cancer

Clinical studies and Clinical trials

Digital Health and Advanced Imaging

Healthcare implementation – *majority explicitly aim to reach TRL 6 to 9 and include health-economics aspects*

Selected proposals have the potential to deliver important impacts and benefits for healthcare systems, healthcare companies and patients, and help IHI achieve it's objectives.



Stay in touch



Visit us

www.ih.europa.eu



Write to us

infodesk@ih.europa.eu



Sign up
for our newsletter



Connect with us



LinkedIn

Innovative Health
Initiative (IHI)



Bluesky

[@ihieurope.bsky.social](https://bsky.app/profile/ihieurope.bsky.social)



Mastodon

[@IHIEurope@mastodon.social](https://mastodon.social/@IHIEurope)



Questions and answers session

The Innovative Health Initiative (IHI): engagement with Industry and preparing for IHI Call12

Enrique Esquivel, Strategy & Innovation manager, COCIR

Nicolas Creff, Associate Director Research Partnerships, EFPIA

Sophie Koettlitz, Manager, Research & Innovation, MedTech Europe

Nathalie Piton, Head of Public Private Partnerships - Alliance Management, Sanofi

Philippe Bordes, Global Alliance Manager - Public Private Partnerships, Sanofi

Nathalie de Préville, Public-Private Partnerships Director, Servier

Information Event France - October 13, 2025



Outline

- **Introducing the Trade Associations: who we are, what we do and what is our role in IHI**
- Why participate in IHI calls?
- How to participate in IHI call 12?
- How to engage with industry?

The Innovative Health Initiative

- A public-private partnership
- Co-founded by the European Union and the health industries (pharma and metchech)
- Established under the **Horizon Europe** Programme, successor to the IMI2 PPP
- **General objectives:**
 - turn health research and innovation into real benefits for patients and society;
 - deliver safe, effective health innovations that cover the entire spectrum of care – from prevention to diagnosis and treatment – particularly in areas where there is an unmet public health need;
 - make Europe's health industries globally competitive.

<https://www.ihp.europa.eu/about-ihp>

Who are the healthcare industries in IHI?

Trade Association	Represents	Mission/Vision
EFPIA 	Pharmaceutical industry	To create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
COCIR 	Medical imaging, radiotherapy, health ICT and electromedical industries	Our industry delivers innovative, data-driven, safe and efficient diagnostic imaging, radiotherapy and digital health solutions for personalized and sustainable care that benefits patients, health professionals and healthcare system.
MedTech Europe 	Medical Technology industry	Make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.
Vaccines Europe 	Vaccine industry	To support broad access to immunisation, enabling better protection of the health of individuals and the wider community throughout life, with both existing vaccines and those in development.
EuropaBio 	Biotech industry	Committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy.

What do associations do?


- **Represent the respective healthcare industry sector vis-à-vis the EU Institutions and other stakeholders**
- Work on IHI represents only one part of our activities, the function and work of associations is considerably more extensive
- The purpose, activities and membership rules are laid out in each membership's statutes
- We represent our industries via direct membership and via national associations



What do associations do in IHI?

- Represent the respective healthcare industry sector in IHI
- We provide support related to industry participation in IHI:
 - We do not replicate the work of the IHI Office!
 - We are not NCPs or consultancies: we do not provide support in proposal preparation or bilateral matchmaking services
 - We work with members (corporate and national associations) to ensure mutual visibility in/of IHI
 - We are active in providing tailored information (e.g. how to engage with industry)
 - We collect and address feedback from stakeholders towards industry

IHI: A public-private partnership



Collaboration extends to:

- Programming
- Financing
- Public and private partners collaborating in individual projects

Industry associations: membership

Who are our members who can contribute on the industry side?

--> Companies that are:

- **Direct members of the European Associations:** [COCIR](#), [EFPIA](#), [EuropaBio](#), [MedTech Europe](#), [Vaccines Europe](#).
- **Members of national associations** (eg [LEEM](#), [SIDIV](#), [Snitem](#))
For all countries: see table [here](#)


See also industry one-pager: [*How can my organisation contribute in-kind to an IHI project?*](#)

Outline

- Introducing the Trade Associations: who we are, what we do and what is our role in IHI
- **Why participate in IHI calls?**
- How to participate in IHI call 12?
- How to engage with industry?


Healthcare stakeholders

Potential participants to projects



- The **complementary value** that the industry brings to the table

Example on rare diseases:



What makes IHI different from regular Horizon Europe calls

- IHI equally associates the EC and Industry in priority setting
- Each IHI project requires ideally **50% of the budget from industry**...unlike Horizon where there is no minimum funding from industry
- IHI aims at delivering (direct and concrete) **impact on the healthcare delivery**
- The **average budget of an IHI project is usually >15 M€**, sometimes much more (ex: 60 M€)... unlike Horizon projects with budget on average <15 M€

IHI for companies:

Value of participating in IHI

- IHI is **more than a funding vehicle**
- **Strategic commitment** and investment in the **long term**
- **Pre-competitive**: no product around the corner
- Collaboratively **building landscape** for long term European research and healthcare
- **Share and pool knowledge** – be part of long-term shaping of Europe
- Grant **funding should not be driver** for industry participation*
- Most industrial engagement will be through in-kind contribution

Advice we give companies to consider for a role into a project:

- Within your **capacity to contribute diverse expertise, knowledge, experience, and resources**
- Part of wider organisation **strategic development**
- **Long term**, slower moving than 'normal' projects

Outline

- Introducing the Trade Associations: who we are, what we do and what is our role in IHI
- Why participate in IHI calls?
- **How to participate in IHI call 12?**
- How to engage with industry?

Up-to-date information always on the IHI website

Learn about our future calls for proposals

We publish draft information on future call topics a few months ahead of the official call launch. We do this to give you additional time to find or build a consortium and prepare a strong proposal. Note that as draft topics are still under development, the texts may change considerably between the versions published here and the call launch, and you should always check the final, approved topic texts once the calls are launched.

IHI to continue pioneering applicant-driven approach in next call for proposals

IHI call 12, which is scheduled for launch in early 2026, will invite applicants to explore new opportunities for IHI projects in the [IHI Strategic Research and Innovation Agenda](#).

The call builds on the success of IHI call 9, which was launched earlier this year and piloted the applicant-driven approach. Under IHI call 12, proposals will have to adhere to the philosophy of IHI. In other words, they will have to: address an unmet public health need; require a large-scale, ambitious, cross-sector, public-private partnership; have clearly-described impacts on society, the economy and science; take account of the pre-competitive nature of IHI projects; and contribute to strengthening the competitiveness of the EU's health industries and the implementation of relevant EU policies.

From a practical point of view, IHI call 12 will be a standard, single-stage call for proposals. This means that applicants will have to ensure that half of their project's costs are covered by in-kind contributions from IHI's industry members and (if relevant) IHI contributing partners.

Find out more

- Read our [news story](#) about the call
- Register for our [brokerage platform and event](#). The event will be held in Brussels on 4-5 November, and online on 6 November. The platform will remain open until the call deadline.

Don't wait until
the official call
launch: start
networking with
partners on
potential projects
as soon as draft
texts are available

[Open calls](#): Check out our calls that are open for full proposals (single-stage) or short proposals (two-stage).
[Future opportunities](#): Learn about the topics that are in the pipeline for future calls for proposals.

Call 12 to be launched in January 2026: draft texts already available mid-October 2025

IHI call 12, scheduled for launch in early 2026, to invite applicants to explore new opportunities for IHI projects in the [IHI Strategic Research and Innovation Agenda](#) (SRIA)

SRIA focuses on the specific objectives of IHI:

1. Improve our understanding of the factors that affect our health and the development and treatment of certain diseases.
2. Integrate fragmented health research and innovation efforts by bringing together health industry sectors and other stakeholders. This will enable the development of tools, data, platforms, technologies and processes that will in turn facilitate the prevention, diagnosis, treatment and management of diseases, especially in areas where there is an unmet public health need.
3. Demonstrate the feasibility of integrated healthcare solutions that draw on various technologies from different sectors and address the needs of the people who will use them, such as patients and healthcare professionals.
4. Make better use of opportunities to gather health data and use it in research and care, all while respecting relevant privacy legislation.
5. Develop ways of assessing the value of innovative, integrated health care solutions to patients, carers, healthcare professionals and organisations, and other stakeholders

2 types of calls

Single-stage (Call 12, early 2026)

- **Broad topics**, not specific to one single product/technology/solution
- **Private Members apply simultaneously with Public Members in mixed consortia** and co-develop their proposal for the single application
- Private Members can receive funding, but Pharma companies abstain from requesting funding
- **In-kind contributions** by private and contributing partners must be **secured during proposal preparation**

Two-stage (Call 13, later in 2026)

- Targeted topics suited for a single, unified approach
- Industry and public consortia are formed separately
- Public consortia submit competing short proposals in the first round of the call
- A single top-ranked public consortium is selected and paired up with the industry consortium to prepare a joint, full proposal
- Private Members are not eligible for funding and no funding will be made available for companies with > 500M EUR annual turnover
- Industry contributions are committed prior to call launch: no need for public participants to secure further in-kind contributions

Outline

- Introducing the Trade Associations: who we are, what we do and what is our role in IHI
- Why participate in IHI single-stage calls?
- How to participate in IHI call 12?
- **How to engage with industry?**

IHI Brokerage event for IHI's 2026 calls

<https://ihicalldays2025.converve.io/>

how to find info on proposals, meet partners potentially interested to participate-contribute in a given proposal

Your personal homepage

The platform will remain open for networking until the call deadline

0% Activity

DOWNLOAD PROGRAMME

Welcome to the IHI Brokerage Platform!



The brokerage platform allows you to showcase your own and your organisation's expertise, and share project proposals with other participants. Once you've registered, you will be able to search for and contact potential partners and identify project proposals that could be relevant for you.

The platform will remain open for networking until the call deadline.

Share your project proposal



Got a proposal for an IHI project that fits with our call?

Share it with other stakeholders and start building your consortium via our proposal sharing tool. Click [here](#) for advice on what makes a good proposal.


SHARE YOUR PROPOSAL

Present your project proposal at the Brokerage Event



To facilitate the formation of strong consortia, we encourage anyone with a proposal for an

Showcase your organisation with a poster at the Brokerage Event



Organisations who want to showcase their potential as a project partner will be easy to find

→ Check info and the search filters in:

- Dashboard
- Get the most out of the Brokerage Event
- Programme
- People
- Proposals
- My proposals
- Pitching
- Poster
- Travel grants
- Practical information
- FAQ
- Messages

Important for you to know: how does industry contribute

- **Industry contribution has to be balanced with IHI funding overall at programme level**
- Therefore, expectation that each project provides a 1:1 matching
- Legal requirement is that each application's budget has **at least 45% of private contribution**. To be on the safe side & plan for any mitigations → **go for 50%**
- **What does industry contributions consist in:**
 - IKOP (in-kind in projects): personnel, consumables, subcontracting, clinical studies, organisation of meetings, equipment...
 - IKAA = additional activities contributing to project objectives / IHI objectives (costs usually similar to above)

Important: subject to HE rules, therefore based on actual costs incurred during the project, not on value

- **Companies' commitments usually require green light at management level:**
 - In single-stage calls: reaching out to companies one month before the deadline is simply too late
 - Two-stage calls: we cannot launch call topics without upfront commitments


Views from industry

- Why and how they engage in IHI?
 - Sanofi
 - Servier

Tips for finding partners

- **Start early!** Consortia start forming as soon as draft topics are released (e.g., i.e. 6 to 7 months before submission deadline)
- **Be proactive** and be prepared to invest time and energy
- Good starting point: **build on your existing network**
- Think of **industry as *partners in a collaborative project***, not as suppliers or future customers
- Be aware of the high intensity of matchmaking, make sure to share **relevant information** concisely:
 - Who are you and what is your expertise?
 - Why are you reaching out (e.g. responding to a pitch, proposing a new idea...)?
 - What is your interest in this topic?
 - Keep in mind the concept of IHI: why does your idea need a public-private partnership?
- Pay attention to the rules on consortium size / composition
- Use the **consortium agreement template** developed by ind. specifically for IHI

Stay in touch



ihi.europa.eu

- Sign up for the [monthly newsletter](#)
- Bluesky: [@ihieurope](#)
- LinkedIn: [Innovative Health Initiative \(IHI\)](#)
- Questions? infodesk@ihi.europa.eu

Further contacts in industry

- **COCIR:** Enrique Esquivel esquivel@cocir.org
- **EFPIA:** Nicolas Creff nicolas.creff@efpia.eu
- **EuropaBio:** Claire Skentelbery C.Skentelbery@europabio.org
- **MedTech Europe:** Jeroen Schuermans j.schuermans@medtecheurope.org
- **Vaccines Europe:** Charlotte Vernhes charlotte.vernhes@vaccineseurope.eu

Thank you for your attention



BACKUPS:

About industry associations





About EFPIA



The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the **biopharmaceutical industry** operating in Europe

Through its direct membership of **37 national associations**, **40 leading pharmaceutical companies**, and a growing number of **small and medium-sized enterprises (SMEs)**, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy



About EFPIA



58

staff members



40

member
companies



37

member
associations



38

partners
in research



14

 **Vaccines Europe**
An industry for healthy lives
members



15

SMEs

The pharmaceutical industry in Europe – selected figures

R&D expenditure: EUR 50 billion

Employment in Europe: 900'000

R&D employment in Europe: 130'000

Trade balance: EUR 200 billion

IMI & IMI2: commitment of EUR 2.4 billion € to almost 200 projects

Source: ***The Pharmaceutical Industry in Figures 2024***: <https://efpia.eu/media/2rxdkn43/the-pharmaceutical-industry-in-figures-2024.pdf>

See also:

- EFPIA Data Centre incl. details on [R&D investment EU & worldwide](#)
- [EFPIA Pipeline Innovation Review 2022](#)

From IMI to IHI

The value of Public Private Partnerships Europe's Partnership for Health



The Innovative Medicines Initiative: The largest public-private partnership for health research worldwide

€5,276 billion

IMI1 €2 billion from 2008-2014

IMI1 €3,276 billion from 20014-2024

Part of the EU FP7 and
Horizon 2020 R&D funding



Tools methodologies



Infrastructures



Standards



Accelerators



The Innovative Health Initiative

Budget over 7 years

€1.2 billion funding from EC

€1.2 billion in kind from industry and contributing partners

Institutional partnership with the EU (Joint Undertaking)

Cross sectoral between

- Pharmaceutical sector (EFPIA, Vaccines Europe, EuropaBio)
- Medical technologies sector (MedTech Europe, COCIR)

EFPIA member companies

Full members



Affiliate members



EFPIA member companies

EFPIA SME members



EFPIA member companies

Partners in research

APEIRON BIOLOGICS



BASF
We create chemistry



charles river

ELLEGAARD
GÖTTINGEN MINIPIGS



FUJIFILM
Value from Innovation



icumedical
human connections

illumina®



IMS Health & Quintiles are now
IQVIA



Life Molecular Imaging
HEALTH CARE

Lonza

McKinsey
& Company



Medtronic



nanoString



PsychoGenics
Transforming CNS Discovery



SVAR



Viscofan
BIOENGINEERING
Your partner for medical collagen



zoetis


EFPIA member associations

Full members

- | | |
|--|---|
| 1  | 11  FARMINDUSTRIA |
| 2  | 12  INFARMA |
| 3  | 13  LMI |
| 4  | 14  The research-based pharmaceutical industry |
| 5  les entreprises du médicament | 15  Pharma Industry Finland |
| 6  | 16  |
| 7  | 17  |
| 8  Die forschenden Pharma-Unternehmen Research-Based Pharmaceutical Companies | 18  Association of Research-Based Pharmaceutical Companies |
| 9  | |
| 10  CHEMISCHE INDUSTRIE | |

Affiliate members

- | | |
|---|--|
| 1  | 11  |
| 2  | 12  |
| 3  THE INDEPENDENT PHARMACEUTICAL INDUSTRY ASSOCIATION | 13  |
| 4  Association of Pharmaceutical Researchers and Developers | 14  |
| 5  ASSOCIATION OF INNOVATIVE PHARMACEUTICAL PRODUCERS | 15  |
| 6  ASSOCIACIÓ INNOVATIVA DE FARMACÈUTICS D'INICIATIVA | 16  |
| 7  Dedicated to Life | 17  |
| 8  ASSOCIATION OF INNOVATIVE PHARMACEUTICAL PRODUCERS NEW MEDICINE, NEW HOPE | 18  |
| 9  | |
| 10  | |



leem
les entreprises
du médicament

Vaccines Europe members

Vaccines Europe (VE) is the specialised vaccine industry group within EFPIA. It represents major innovative research-based global vaccine companies as well as small and medium sized enterprises operating in Europe.



The voice of biotechnology in Europe



Ensuring an innovation pipeline for a competitive Europe

The right strategic, legislative and regulatory frameworks for biotechnology to thrive

National, European and global representation

EuropaBio works with company members and national associations across sectors to champion biotechnology

- Bringing **Innovation** to all citizens – making a difference to you
- Enabling **Investment** to deliver next generation technologies to market – creating value & jobs
- Delivering **Excellence** across science and society – translating Europe's research into European benefits

Healthy people and planet

EuropaBio Members

CORPORATE MEMBERS



abbvie



BIOMARIN




Bon Vivant



dsm-firmenich



MEATABLE



National associations

NATIONAL ASSOCIATIONS AND BIO REGIONS



ASSOCIATE MEMBERS



The medical technology industry associations



- Medical Devices
- In-Vitro Diagnostics
- Digital health solutions



- Radiotherapy
- Medical imaging
- Health ICT
- Electromedical

The MedTech Industry in Europe



€ 170
billion market



930,000+
employees



38,000+
Medical technology
companies of which
90% are SMEs



2,000,000+
medical technologies
(Medical Devices,
In-Vitro Diagnostics,
Digital Health)



#4 highest
In filing patent applications among all industrial
sectors

About MedTech Europe

The European trade association for the medical technology industry including **diagnostics**, **medical devices** and **digital health**.

OUR MEMBERS



150+ multinational corporations*

*medical devices, diagnostics and digital health



50+ medical technology associations



PURPOSE

MedTech Europe's purpose is to make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.

MISSION



Be the **European voice** of the medical technology industries – in Europe and beyond



Highlight the **value** and **contribution** of medical technologies, services and solutions for **patients**, **healthcare systems** and **society**



Facilitate access to **needed medical technologies**



Be a **trusted partner** to EU policymakers and key stakeholders



Contribute actively to EU health-related **policies and legislations**



Foster the **highest ethical standards** in all interactions between the industry and HCPs and HCOs

Based in Brussels, Belgium with 50 staff members



MedTech Europe priorities

- Legal and Compliance
- Market Access and Economic Policy
- Medical Technology Regulations
- Digital Health
- International Affairs
- Environmental and social sustainability
- Market data
- **Research and Innovation**
- + sector groups: e.g. cancer, diabetes, cardiovascular, AMR, Robotic Assisted Surgery,

More info: www.medtecheurope.org



MedTech Europe priorities via IHI

Europe's attractiveness and competitiveness as an industrial location for innovation via 3 axes:

- Sustainability
- Digital, AI and RWD
- Healthcare delivery improvement

Introduction to COCIR



MEDICAL IMAGING

- Computed Tomography scanners
- Ultrasound
- Nuclear Imaging
- Radiation therapy equipment
- Magnetic Resonance Imaging
- Imaging Information Systems
- Medical X-Ray equipment

RADIATION THERAPY

- Brachytherapy
- Nuclear Medicine
- Proton Therapy
- Systemic Radiation Therapy
- External Beam Radiation



ELECTROMEDICAL EQUIPMENT

- Patient Monitoring
- Intensive Care equipment
- Electro Surgery

DIGITAL HEALTH

- Medical Imaging Information Technology
- Enterprise Information Technology
- Hospital Information Systems
- Clinical Information Systems
- Electronic Health Records
- Telemedicine
- Mobile Health



- COCIR is a non-profit trade association, founded in 1959 and having offices in Brussels and China, representing the medical technology industry in Europe
- COCIR covers 4 key industry sectors
 - Medical Imaging
 - Radiotherapy
 - Health ICT
 - Electromedical
- Our Industry leads in state-of-art advanced technology and provides integrated solutions covering the complete care cycle



Company Members

ACCURAY

AGFA Agfa
HealthCare

AGFA Agfa


aidence
human sense in artificial intelligence

Alcon



BARGO



Canon
CANON MEDICAL

Carestream

CMR
SURGICAL

 **Dedalus**
HEALTHCARE SYSTEMS GROUP

 **Elekta**

EOS
imaging

Epic

esaote

FUJIFILM

 **GE HealthCare**

HOLOGIC
The Science of Sure


HUAWEI




KONICA MINOLTA

 **LUXIUM**
SOLUTIONS



SAMSUNG

SIEMENS
Healthineers



National Trade Associations Members



FINLAND



FRANCE



GERMANY



GERMANY



HUNGARY



ITALY



PORTUGAL



THE NETHERLANDS



THE NETHERLANDS



SPAIN



SWEDEN



TURKEY